MICHAEL SANDERS: Open Payments
NPI 1548698954 · SEBRING, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$938 in 44 payments from 13 companies in 2025. Trend: 2023 $263 · 2024 $442 · 2025 $938
Food & beverage: $938
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $165 |
| Alkermes, Inc. | 8 | $152 |
| Teva Pharmaceuticals USA, Inc. | 5 | $118 |
| ABBVIE INC. | 5 | $109 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Neurocrine BioSciences, Inc. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
Products named: REXULTI, ARISTADA, AUSTEDO XR, VRAYLAR, COBENFY, INGREZZA, CAPLYTA, Auvelity.
Industry payments across FL — which companies pay providers there.
